24 Academic Centers.
One Shared Mission.
Advancing therapies for Waldenström’s Macroglobulinemia
Improving the lives of people with WM by designing, testing, and delivering the next generation of transformative treatments.
WM-Net is the premier clinical trial network dedicated exclusively to advancing innovative therapies for Waldenström’s macroglobulinemia (WM).
Comprising 24 leading academic medical centers, WM-Net unites the foremost investigators in the field to accelerate the translation of discovery into patient care.
Transforming Research into Clinical Advances for Patients
WM-Net connects physician-scientists who share a commitment to improving outcomes for people living with Waldenström’s macroglobulinemia. Through scientifically driven clinical trials and translational research, WM-Net investigators identify the most important unanswered questions in WM and design studies to address them. Our nationwide collaboration enables:
Rapid activation of multi-institutional studies
Faster patient access to new therapies
Broader participation of underrepresented populations
Seamless sharing of data and best practices
Leaders in Innovation.
Partners in Care.
The nation’s foremost WM clinicians and scientists united to accelerate progress.
Behind every WM-Net study is a community of dedicated clinician-scientists driven by a shared vision: improving outcomes for individuals with Waldenström’s macroglobulinemia.
WM-Net’s leadership includes its founding director, Dr. Jorge Castillo (Dana-Farber Cancer Institute), and a national team of investigators representing 24 leading academic medical centers.
WM-Net Leadership Team
Our 24 Centers
WM-Net Clinical Trials
Innovative studies designed and led by academic investigators to bring new treatments within reach.
WM-Net coordinates a portfolio of multi-center clinical trials investigating next-generation therapies for Waldenström’s macroglobulinemia.
Preview ongoing studies here and follow links for eligibility details and enrollment sites.
Founded on Collaboration and Compassion
Established in 2024 with support from the International Waldenström’s Macroglobulinemia Foundation (IWMF) and the WM community. Together, WM-Net’s investigators, partners, and patient advisors are transforming the landscape of WM research — bridging science and patient care to bring the promise of discovery to every WM patient.